https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

administrator

Related Articles